Skip to main content
PLOS One logoLink to PLOS One
. 2025 Jul 22;20(7):e0328136. doi: 10.1371/journal.pone.0328136

Superior normalization using total protein for western blot analysis of human adipocytes

Leo JS Westerberg 1,#, Benjamin Dedic 1,#, Erik Näslund 2, Anders Thorell 3, Kirsty L Spalding 1,*
Editor: Jérôme Robert4
PMCID: PMC12282925  PMID: 40694567

Abstract

Western blotting has been a pivotal method for analyzing protein expression since the late 1970s, yet there is no established consensus on an optimal normalization strategy. In this study, primary mature human adipocytes were used to investigate the robustness of housekeeping proteins and total protein (TP) as normalization references for western blotting. TP exhibited the lowest variance among technical replicates compared to all investigated housekeeping proteins and was a superior normalization reference for the chosen protein-of-interest. TP also demonstrated the closest alignment with expected values when loaded as a protein gradient, highlighting the dynamic strength of TP as a normalization standard. Additionally, TP consistently demonstrated lower intra- and inter-individual variability in comparison to housekeeping proteins investigated across three metabolically similar individuals. In conclusion, TP normalization is the preferred method for reliable protein expression analysis in primary mature human adipocytes.

Introduction

Western blotting is a widely used technique for the semi-quantitative assessment of protein levels. The method was first developed in the late 1970s [1,2] and along with improvements remains relevant today. While many variations of the method have been established, the fundamentals persist: Proteins are separated by size using electrophoresis and subsequently quantified using antigen-specific reagents. As antigen detection correlates with the amount of protein loaded, normalization is implemented to correct for variations between loaded samples, thereby enhancing the accuracy of comparisons across multiple samples.

Historically, housekeeping proteins such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH), actin, and tubulin have been used to control for loading and transfer inconsistencies. These proteins are considered housekeeping proteins because they are fundamental to normal cell function and are thus constitutively expressed across all cells and tissues. Consequently, these housekeeping proteins can be quantified and utilized as normalization references to accurately compare proteins of interest across multiple samples. Numerous studies, however, have demonstrated that housekeeping proteins are variable, both across cell lines [35] and various human tissues, such as the human cortex [6], cerebrospinal fluid [7], skeletal muscle [8] and human placenta [9]. Whilst housekeeping proteins have been studied for their reliability in adipose tissue [10], we investigate their applicability for studies in isolated adipocytes and compare normalization using housekeeping proteins to an alternative method, namely total protein (TP) normalization.

In contrast to the use of specific housekeeping proteins, TP utilizes dyes, or other chemistry, to produce a signal that represents the entire protein content of a sample. Building on this approach, TP normalization effectively eliminates the drawbacks of individual protein expression variability and more accurately reflects the true sample load [1113]. Common staining methods for TP include Coomassie Brilliant Blue, Ponceau Red, Amido Black and SYPRO Ruby staining. Despite their effectiveness in reflecting TP content, the above-mentioned TP methods introduce additional wash and de-staining steps, extending the already lengthy process of western blotting. To maintain the advantages of TP normalization while simplifying the process, stain-free technology was developed. Stain-free technology utilizes a trihalo compound that can be incorporated into electrophoresis gels where they covalently bind to tryptophan residues upon UV activation. This creates a complex that emits fluorescent light directly proportional to the number of complexes [14], enabling quick TP detection without washes or de-staining.

Despite these established advantages, TP normalization has not yet achieved universal adoption in western blot analysis. The persistence of traditional housekeeping protein methods can be attributed to several factors, i) historical precedent has maintained housekeeping proteins as the default choice in many laboratories, particularly given their extensive representation in published literature, ii) early iterations of TP detection methods introduced technical complexities and potential interference with subsequent immunodetection steps and iii) the requirement for specialized imaging equipment and standardized detection protocols has posed implementation barriers. Moreover, the diverse array of TP detection methods, from classical chromogenic stains to stain-free technologies, has limited the establishment of a unified normalization protocol.

Considering the advantages of TP normalization, this study investigates if stain-free based TP normalization is a more suitable alternative to traditional housekeeping protein normalization in western blotting of primary mature human adipocytes.

Materials and methods

Ethics

All experiments were performed in accordance with the statutes of the Declaration of Helsinki. The study was approved by the regional ethics committee in Stockholm (Regionala etikprövningsnämnden i Stockholm, 2014/1115–31 and 2017/1156-32). Sample collection for this study began on 9th of September 2021 and continued through 13th of March 2023 at both Ersta Hospital and Danderyd Hospital, Stockholm, Sweden. Informed written consent was obtained from all participants prior to surgery.

Human samples

Human surgical biopsies from omental (OM) and abdominal subcutaneous (SC) white adipose tissue were obtained from 9 individuals with obesity undergoing bariatric surgery at Ersta Hospital (n = 6) or Danderyd Hospital (n = 3) in Stockholm, Sweden. Individuals were fasted overnight and blood glucose, plasma insulin and c-peptide were measured either the morning of surgery (Ersta Hospital) or 2 weeks prior to surgery (Danderyd Hospital). Bloodwork was analyzed at the Karolinska Universitetslaboratoriet. A summary of clinical and metabolic parameters of the full cohort can be found in S3 and S4 Tables.

Adipocyte isolation

Adipocytes were extracted from the tissue sample using the method outlined in [15], with the only difference being the exclusion of Bovine Serum Albumin (BSA). In brief, the tissue sample was finely minced and subjected to digestion in Krebs-Ringer-phosphate buffer (containing 127 mM NaCl, 12.3 mM NaPO4, 1.36 mM CaCl2, 5.07 mM KCl, 1.27 MgSO4, pH 7.4) that had 0.05% collagenase I from Clostridium histolyticum (Sigma, #C0130), 5 mM D-glucose and 50 μg/ml gentamicin. Digestion took place in a 37°C oscillating water bath for 45−60 minutes. Residual undigested tissue was filtered out using a 250 μm nylon filter. Adipocytes were washed three times with a wash buffer comprising of 5 mM D-glucose and 50 μg/ml gentamicin in DPBS (Gibco, #14190−136) at pH 7.4. After the final wash, the cells were transferred to 2 mL tubes, rapidly frozen in liquid nitrogen and stored at −80°C for subsequent protein extraction.

Protein extraction and quantification

Frozen adipocytes were mixed at 2:1 with 1% SDS buffer (Sigma, #05030–500ML-F) supplemented with HaltTM Protease & Phosphatase Single-Use Inhibitor Cocktail (100X) (Thermo Scientific, 1:100, #78442). The mixture was heated at 95°C for 5 minutes using a heating block, followed by incubation on a rocker at room temperature for 15 minutes. Samples were centrifuged at 14.000 rcf for 10 minutes and the aqueous phase transferred to a new tube. Protein concentrations were determined using a PierceTM BCA Protein Assay (Thermo Scientific, #23227). Absorption was measured using FLUOstar OPTIMA spectrophotometer and protein concentrations calculated using a linear regression model fitted to the BSA standard (125–2000 ng/µL), accounting for blanks.

Western blot

For each sample, 10 µg of protein was mixed with 4x Laemmli buffer (BioRad, #1610747) supplemented with 2-Mercaptoethanol (BioRad, #1610710) at 1:3 in 0.5 mL tubes. Samples were heated in a heating block at 95 °C for 5 min and subsequently centrifuged at 20817 rcf for 1 min. Running buffer was prepared by mixing 100mL of 10x TGS stock solution (BioRad, #1610772) with 900 mL ddH2O. Precast Mini-PROTEAN TGX Stain-Free Gels (BioRad, #4568094) were used for gel electrophoresis. 3 µL of Precision Plus Protein Unstained Standards (BioRad, #1610363) was loaded in the far left well and protein samples in the remaining wells. Gel electrophoresis was run at 200V for approximately 40 min with a PowerPacTM Basic (BioRad, #1645050).

After electrophoresis, the gel was activated in the ChemiDocTM MP Imaging System (BioRad, #12003154) using stain-free technology. Prior to assembling the transfer stack, a low fluorescence (LF) PVDF membrane was activated in pure methanol (Sigma-aldrich, #32213-1L-M) and filter papers soaked in 4°C 1x transfer buffer (Trans-Blot Turbo RTA Transfer Kit LF PVDF, BioRad, #1704274). A transfer stack was constructed in the Trans Blot® TurboTM Transfer system (BioRad) and a mixed molecular weight protein transfer program was run for 7 min. The membrane was imaged in the BioRad ChemiDoc MP imaging system using stain-free UV activation for TP quantification as well as to ensure successful protein transfer had occurred.

Immunoblotting

The membrane was blocked in EveryBlot Blocking Buffer (BioRad, #12010020) for 10 min on a shaker at RT. After blocking, the membrane was incubated with primary antibodies O/N on a shaker at 4°C. Primary antibodies, all commercially validated, were prepared in 10 mL 5% milk (Millipore, #70166-500G) at the following concentrations; BSA (Life, 1:1000, #A11133), GLUT4 (ProteinTech, 1:500, #66846–1-Ig), PARK7 (Abcam, 1:500, #ab18257), ENOA (MyBioSource, 1:250, #MBS9231722) and FAH (Invitrogen, 1:500, #PA5−42049). After primary antibody incubation, the membrane was washed 3 times in TBS supplemented with 0.05% tween-20 (TBST) (ChemCruz, #SC-362311) and incubated with secondary antibody for 1 hour at RT. Secondary antibodies and GAPDH, actin or tubulin were prepared in 10 mL 5% milk (in PBS) at the following concentrations; Anti-Mouse IgG H&L HRP conjugated (Abcam, 1:5000, ab205719), hFAB Rhodamine Anti-GAPDH (BioRad, 1:1250, #12004167), hFAB Rhodamine Anti-Actin (BioRad, 1:1250, #12004163), hFAB Rhodamine Anti-Tubulin (BioRad, 1:2500, #12004165) and depending on the housekeeping used, StarBright Blue 700 Goat Anti-Rabbit IgG (BioRad, #12004161) diluted either at 1:2500 (PARK7 and FAH) or 1:5000 (ENOA). The membrane was washed twice in TBST and once in DPBS (Gibco, #14190−136) and imaged in the ChemiDoc MP imaging system. Housekeeping proteins were imaged at 700nm (PARK7, ENOA or FAH), followed by rhodamine conjugated housekeeping proteins, GAPDH, actin or tubulin. The membrane was incubated in 5 mL SuperSignalTM West Femto Maximum Sensitivity Substrate (Thermo Scientific, #34096) ECL mix for 5 min on a shaker at RT. Lastly, GLUT4 was imaged using chemiluminescence.

Western blot analysis

The volume tool in ImageLab software (BioRad) was used to analyze stain-free images of the membranes, taken immediately post transfer. Housekeeping proteins and GLUT4 band intensities were determined utilizing the lane and band tool in ImageLab. Visualization of data and statistics were performed using Prism 9 software (GraphPad).

Western blot normalization

In fixed point normalization, the choice of reference point can introduce a bias [16]. If the selected reference point does not accurately represent the tendency or the range of the data, it can skew the normalized values. This bias can lead to misinterpretation of results, as the normalized data might disproportionately emphasize certain values while under representing others.

To avoid fixed point normalization bias, data was normalized by first dividing the intensity of each band/lane by the total intensity of all bands/lanes within each blot (in Equation 1 shown below, denoted as the ‘observed fraction of total intensity’). This fraction was then divided by the expected ratio (denoted in Equation 2 as the ‘expected fraction of total intensity’), i.e., the theoretical ratio obtained by dividing the intensity of a given band by the total sum of intensities for all bands/lanes (S1 Fig and S1 Table).

Normalization calculations

  1. Calculate the Fraction of Total Intensity:

  Observed Fraction of Total Intensity = Band Intensity Σ Band Intensities 

This step determines the proportion of the total intensity contributed by each band.

  1. Calculate the Deviation from Expected Intensity:

Deviation from Expected Intensity =Observed Fraction of Total Intensity Expected Fraction of Total Intensity 

This step compares the observed fraction of total intensity to the expected fraction, resulting in:

> 1 if the observed intensity is higher than expected

< 1 if the observed intensity is lower than expected

= 1 if the observed intensity matches the expected intensity

Following established statistical protocols, the coefficient of variation (CV) was selected to assess the measured variability (precision) of normalization references both within technical replicates [5,7,9] and across a dynamic range of protein loading [17,18] CV was calculated using the deviation values obtained from the equations above. The standard deviation was divided by the mean of the deviation values and multiplied by 100 to generate a percentage using Prism 9 software (GraphPad), quantifying the relative variability in protein expression across experimental conditions [610].

Simulation of normalization reference variability

To demonstrate the universal impact of normalization reference variability on protein quantification precision, simulated western blot data was generated using seeded random number generation. A protein of interest data set with realistic technical variability (CV = 19.9%) was created using the Box-Muller transformation to generate normally distributed values around a mean of 1. Normalization reference datasets with systematically increasing coefficients of variation (5%, 15% and 30%) were similarly generated using different random seeds to ensure independence. Optimal seeds were identified through iterative searching to achieve target CVs within ±1% tolerance. Normalized protein values were calculated as the ratio of protein of interest to reference values, and CVs were determined as described above.

Results

Theoretical impact of normalization reference variability on protein quantification

The precision of Western blot protein quantification is fundamentally determined by the variability of the normalization reference, independent of the specific protein being analyzed. To demonstrate this principle, simulated identical protein of interest (POI) data representing realistic technical variability (CV = 19.9%) was normalized using references with systematically increasing variability ranging from 5% to 30% CV (S2 Fig).

Normalization of the POI using a stable reference (5% CV) resulted in a final CV of 16.6%, closely maintaining the precision of the original protein signal (S2 Fig). However, as reference variability increased, the precision of the normalized POI deteriorated progressively. Normalization using moderately variable references (15% CV) inflated the normalized protein variability to 30.6% CV (S2 Fig). Notably, normalization using highly variable references (30% CV) resulted in final CVs of 47.0%, representing a 2.8-fold increase in variability compared to stable reference normalization (S2 Fig, 16.6% vs 47.0%). This analysis demonstrates that normalization reference selection determines normalized protein precision regardless of the protein target (S2 Fig). The 2.8-fold difference in variability occurred with no change in the underlying protein signal, confirming that these effects represent universal analytical principles rather than protein-specific phenomena.

These simulations assume identical loading conditions with CVs reflecting only imprecision in signal readout and/or reference stability. It should be noted that simulated datasets do not incorporate biology such as potential correlations between normalization references and target proteins, which falls outside the scope of this study.

To validate this principle experimentally in primary human adipocytes, GLUT4 was selected as a representative POI to compare TP and housekeeping protein normalization performance.

BSA contamination in adipocyte isolation and its impact on western blotting

Prior to investigating the suitability of TP normalization in primary mature human adipocytes, the presence of potential protein contaminants from the adipose tissue isolation protocol was assessed. In previous western blot analyses using mature human adipocytes, strong TP bands around 60 kDa were consistently observed, suggesting potential protein contamination (Fig 1A). Bovine serum albumin (BSA) (kDa 65), which is commonly used in adipocyte isolation protocols to enhance cell survival and overall viability, was suspected to be a contributing factor to this contamination. To investigate this, an adipose biopsy was divided in half and adipocytes were isolated either with BSA (standard protocol), or without BSA (adjusted protocol). No discernible difference in adipocyte yield was seen between standard and adjusted protocols. Following adipocyte isolation, half of the cells from each condition were immediately frozen for protein isolation, while the remaining half were subjected to three washes in PBS prior to freezing. The protein concentration for each lysate was determined using a BCA kit. Despite all samples originating from the same individual biopsy, marked variations in protein concentrations were observed across the different conditions (S2 Table). Notably, the protein concentration of the unwashed BSA-isolated sample surpassed the upper BCA standard, leading to an extrapolated estimate of the exact concentration under linear assumptions (S3A Fig).

Fig 1. Impact of BSA contamination on protein quantification methods.

Fig 1

(A) Stain-free image of total protein (TP) with bands corresponding to 50 and 75 kDa indicated on ladder. Duplicates shown for each condition. (B) BSA (65 kDa), tubulin (55 kDa) and GLUT4 (54 kDa) staining. (C) Average BSA signal from all duplicates, normalized to the smallest value above 0. (D) Average tubulin signal from all duplicates, normalized to the smallest value. (E) Average BSA signal from all duplicates, normalized to tubulin, normalized to smallest value above 0. (F) Tubulin normalized to TP, normalized to the smallest value.

To visualize TP, samples were separated by electrophoresis using stain-free gels, followed by a quick UV activation step. In the unwashed BSA-isolated sample, TP was dominated by a single band in the ~ 60 kDa range, in contrast to a more spread-out profile in BSA-free and washed BSA-isolated samples (Fig 1A). Strong BSA labeling was seen in the ~ 60 kDa range in both unwashed and washed BSA-isolated adipocytes but was not detected in BSA-free samples (Fig 1B, C). The combination of reduced TP at ~60 kDa (Fig 1A) and no BSA detection through antibody labeling in the BSA-free samples (Fig 1B) indicated that BSA introduced significant protein contamination and should therefore be avoided during tissue isolation.

Additionally, BSA contamination increased TP content in the lysate, as shown by BCA readouts (S2 Table). This can lead to underloading of endogenous proteins, highlighted by tubulin measurements (Fig 1B, 1D), or in the ratio of BSA to tubulin (Fig 1E). This issue stems from the limitations of BCA to distinguish between endogenous and exogenous sources of protein. Washing BSA-isolated samples attenuates the contamination effects but does not eliminate TP normalization issues, as tubulin normalized to TP is lower in both washed and unwashed BSA-isolated samples, compared to BSA-free samples (Fig 1F).

To investigate the suitability of TP normalization compared to housekeeping proteins in isolated human adipocyte samples, glucose transporter 4 (GLUT4) was chosen as the protein of interest. GLUT4 antibody staining showed strong bands in the unwashed BSA-isolated sample, with weaker bands in the washed BSA-isolated sample (Fig 1B). Overexposure of the blot showed that the expected GLUT4 signal (~54 kDa) was clearly present in the BSA-free samples while the BSA-isolated samples showed non-specific bands at ~60 kDa (S3B Fig). These results can be explained by non-specific antibody binding to BSA (65 kDa) leading to false positives in BSA-isolated samples but not in BSA-free samples. Thus, subsequent experiments within this study used BSA-free samples, accentuating the importance of limiting BSA, or other protein contaminants, in western blotting.

Normalization reference variability in technical replicates

To determine the optimal normalization strategy for western blot analysis in mature human adipocytes, housekeeping proteins previously validated for adipocyte and obesity research, such as parkinsonism associated deglycase (PARK7), enolase 1 (ENOA), and fumarylacetoacetase (FAH) were investigated [10]. In addition, GAPDH, actin and tubulin were included as global housekeeping markers for a broader comparison. Evaluation of all normalization references was performed using primary mature human white adipocytes. First, the assessment involved technical replicates, where each well in a gel was loaded with 10 µg of protein from the same sample. Samples were obtained from four different individuals: two obese hyperinsulinemic (OBHI) patients (one subcutaneous (SC) and one omental (OM)) and two obese normoinsulinemic (OBNI) patients (one SC and one OM). Each sample was analyzed across three separate blots to assay all housekeeping proteins, allowing for the normalization of GLUT4 levels to two housekeeping proteins and TP within each blot. Data was normalized and visualized such that an increasing deviation from 1 indicated a higher protein variation (S1 Fig, S1 Table, see methods for more details).

Housekeeping proteins, TP and GLUT4 were analyzed independently to investigate potential variability in loading, antibody stain or transfer efficiency. The coefficient of variation (CV) for housekeeping proteins was higher in comparison to TP (Fig 2AF, S4A–F Fig, left-side panels, S4 Fig), except in two instances: FAH exhibited the lowest CV for the OBHI OM sample, and actin had the lowest CV for the OBNI OM sample (Fig 2D, S4F Fig). Notably, GLUT4 demonstrated high CVs prior to normalization in all samples and across all blots (Fig 2AF, S4A–F Fig). GLUT4 was subsequently normalized to both housekeeping proteins and TP to compare the CV between each normalization reference. Unexpectedly, normalization predominantly led to an increased CV for GLUT4 (Fig 2AF, S4A–F Fig, right-side panels). Using TP as the normalization reference resulted in the lowest CV for GLUT4 in most blots (Fig 2A, B, E, F, S4A, B, E Fig). When normalized to actin and ENOA, GLUT4 achieved the lowest CV in two blots each (Fig 2C, D, S4C, D Fig).

Fig 2. Technical replicates from OBNI individuals.

Fig 2

Coefficient of variation (CV) for total protein (TP) and respective housekeeping proteins, normalized to the sum (left panels), and for GLUT4 normalized to TP or housekeeping proteins (right panels). Each dot represents one well – a technical replicate of the same lysate sample run in separate lanes. TP demonstrated the lowest CV across all technical replicate blots, except when compared to actin in the OM sample (A–F). When normalizing GLUT4, TP showed the lowest CV in four blots (A, B, E, and F), while actin (C) and ENOA (D) exhibited lower CVs in two blots.

The CVs resulting from GLUT4 normalization to actin and ENOA showed depot-specific trends: Actin yielded the lowest CVs in SC adipocytes (OBNI and OBHI), while ENOA had the lowest CVs in OM adipocytes (OBNI and OBHI) (Fig 2C, D, S4C, D Fig). This data suggested that actin and ENOA exhibited differing variability within adipocytes from specific adipose depots. Taken together, TP emerged as the most reliable normalization reference, offering lower variability and more consistent CVs for GLUT4 normalization across technical replicates.

Dynamic range of normalization references in single sample loading gradient

To explore dynamic range differences between housekeeping proteins and TP, an OM adipocyte protein lysate from a individual with obesity and hyperinsulinemia was loaded with a protein gradient of 2.5–20 µg, in 2.5 µg increments (n = 8) (S6 Fig). The same normalization approach used for the technical replicates was used to visualize the data (S1 Fig and S1 Table, see methods for more details).

Housekeeping proteins and TP were assessed independently: In all three blots, TP exhibited the lowest CV and was the only normalization reference with a CV lower than 10% (Fig 3AC). Lower protein loads typically resulted in larger deviations from their expected value, which in turn contributed to the overall higher CVs observed in housekeeping proteins (Fig 3AC). Large amounts of lysate can cause signal saturation for highly expressed proteins, such as housekeeping proteins [19], as observed in our study: Signal saturation was observed in FAH where a load of a 7.5 µg and above showed a negligible increase in signal, likely contributing to the high CV (Fig 3C and S6C Fig). No signal saturation was observed in other housekeeping proteins or TP within the tested range.

Fig 3. OBHI OM lysate loaded in 2.5 µg gradient increments (2.5–20 µg).

Fig 3

Lysates were visualized with a color gradient, and the coefficient of variation (CV) was calculated. Total protein (TP) showed the lowest CV across all blots when normalized to the sum (A–C). For GLUT4 normalization, PARK7 demonstrated the lowest CV in one blot (D), while TP achieved the lowest CV in two blots (E and F).

GLUT4 was normalized to TP and housekeeping proteins. As observed with technical replicates, the CVs from GLUT4 normalization generally increased after normalization, regardless of the chosen reference. While GLUT4 normalization to TP yielded the lowest CV in two of three blots, there was considerable variation across all three blots (27.3 vs 15.9 vs 9.6, Fig 3DF). This variability is primarily attributed to the CVs from GLUT4, rather than being substantially influenced by TP variability (Fig 3AC). The signal saturation of FAH within the tested dynamic range highlighted its unsuitability as a reference protein due to the lack of linearity (Fig 3C, F, S6C Fig). A consequence of its insensitivity to protein loads from 7.5–20 µg also likely contributed to an artificially low CV in technical replicates (Fig 2E, F, S4E, F Fig).

Taken together, TP offers a more stable and reliable normalization reference compared to housekeeping proteins across a dynamic range and technical replicates. Variability in normalization with housekeeping proteins, particularly highlighted by FAH, underscores the importance of choosing a dynamic and low-variance reference protein. The relatively lower CV resulting from TP normalization, combined with no signal saturation within the tested dynamic range, suggests that TP as a more fitting normalization reference compared to housekeeping proteins.

Comparing normalization references across samples from multiple individuals

To assess the impact of using different normalization references on GLUT4 levels across individuals, a cohort of three clinically and metabolically similar individuals was studied (S3 Table). Given the varying sensitivities observed at different protein loads during the dynamic range comparisons, samples from each individual were loaded at 5, 10 and 15 µg to minimize biasing based on dynamic range performance. Data were initially normalized to the respective protein loads (i.e., normalized such that 5 µg corresponds to a factor of 1, 10 µg to 2, and 15 µg to 3), and visualized as fold change from the minimum value. This approach was adopted since there is no predefined expected value for each sample when comparing between unique individuals.

Quantification of TP, housekeeping proteins and GLUT4 for each individual demonstrated consistent trends across the three individuals: Individual 1 showed the highest levels of protein expression for all proteins, followed by individual 3, then individual 2 (Fig 4AC, S7 Fig). TP, ENOA, actin, FAH and GLUT4 all displayed minimal variance within individuals when normalizing to protein load (Fig 4AC). This was similar for PARK7, GAPDH and tubulin for individuals 2 and 3, but not for individual 1 (Fig 4AC). When comparing normalization references, TP and actin exhibited a relatively small fold-change (fc) difference between individuals (fc ~ 2), versus PARK7 (fc ~ 6), GAPDH (fc ~ 6), ENOA (fc ~ 5), FAH (fc ~ 4) and tubulin (fc ~ 10) (Fig 4AC).

Fig 4. Protein gradient loading across a metabolically and clinically similar cohort (n = 3).

Fig 4

Lysates were loaded at 5, 10, and 15 µg, visualized with a color gradient, and normalized to the minimum value. Inter- and intra-individual comparisons of normalization references and GLUT4 demonstrated that total protein (TP) exhibited the lowest variability both within and between individuals (A–C). In contrast, housekeeping proteins normalized to TP reveal substantial inter-individual variability (D–F), highlighting that their expression levels differ between patients even when loading is accounted for. GLUT4 normalized to different references (TP or housekeeping proteins) further illustrate how the choice of normalization strategy can markedly influence the apparent between-patient differences (G–I).

To determine if variations in loading amounts were responsible for the substantial differences observed in housekeeping protein expression among individuals, the housekeeping proteins were normalized against TP. While this normalization mitigated the differences in housekeeping expression between individuals, loading amount alone could not account for these variations (Fig 4DF), suggesting that inherent differences in housekeeping protein expression exist even amongst individuals with similar clinical and metabolic profiles.

TP normalization led to comparable expression levels of GLUT4 between individuals 1 and 3, with a notable decrease in individual 2 across all blots (Fig 4GI). When normalized to TP, the fold change difference was approximately 6 in two blots, in contrast to a fold change difference of 3 in one blot. This variability likely stems from the major variations in GLUT4 signal, rather than from the stable TP signal observed in these individuals, with GLUT4 varying approximately 1–10-fold, and TP showing a narrower range of about 1–2-fold (Fig 4AC). When GLUT4 is normalized against PARK7, GAPDH or tubulin, the expression level among the three individuals is consistent (Fig 4G, I). However, normalization using ENOA, actin or FAH reveals distinct difference in expression: Individual 2 consistently showed the lowest levels of GLUT4, while the highest GLUT4 expression shifts between individual 1 when normalized to actin, and individual 3 when normalized to ENOA or FAH (Fig 4H, I).

Collectively, these findings indicated that the choice of normalization reference dramatically affects the determination of GLUT4 expression levels when comparing multiple individuals. Notably, the expression of housekeeping proteins varies widely among individuals with similar clinical and metabolic profiles (Fig 4DF), influencing the normalized values of proteins of interest (Fig 4GI). Among the housekeeping proteins, actin demonstrated smaller inter-individual variability (Fig 4E) and yields normalized GLUT4 expression levels comparable to those obtained when normalizing to TP. Thus, normalization references with minimal intra- and inter-individual variability, such as TP and actin, are necessary for precise protein expression comparison across multiple individuals.

In summary, these findings highlight the importance of using normalization references with low variance both within and among individuals. While actin demonstrated low inter-individual variability, it under performs in both dynamic range and technical replicate analysis. Ultimately, the robust variance of TP in technical replicates, dynamic range and across individuals makes it a superior normalization reference for mature human adipocyte western blot analysis. Table 1 summarizes the performance of TP and housekeeping proteins across all experimental conditions tested, highlighting the overall best normalization reference alongside the most robust housekeeping protein alternative when experimental conditions necessitate housekeeping protein use (e.g., requirement for BSA in the isolation or culture environment).

Table 1. Optimal normalization references for different experimental designs.

Experimental setup Best overall Best housekeeping protein
Technical replicates SC TP FAH
Technical replicates OM TP Actin
Dynamic range TP Actin
Inter-individual comparison TP Actin

Discussion

Western blotting is one of the most widely utilized techniques for protein expression analysis. Despite its popularity, a consensus on the most effective normalization strategy has not been reached. Housekeeping protein normalization was adopted to standardize western blot results. As increasingly sophisticated tools and software for precise protein quantification have become available, TP normalization has emerged as an alternative approach to housekeeping protein normalization. In this study, we compare these two normalization methods in primary mature human adipocyte western blotting, to determine which normalization strategy is superior.

In our study, TP exhibited lower variance compared to both GLUT4 and housekeeping proteins across technical replicate- and dynamic range analyses. The high variance observed in GLUT4 and housekeeping proteins occasionally made normalizing GLUT4 to housekeeping proteins, rather than TP, appear advantageous. However, this apparent co-variance seemed to occur by chance, as GLUT4 and housekeeping proteins sometimes varied concurrently on one blot but independently or in opposing directions on another. Moreover, even minor fluctuations in a housekeeping protein’s expression could significantly skew the normalization process, whereas similar variations in a single protein would have a negligible impact on TP normalization.

Previous research identified PARK7, ENOA, and FAH as suitable housekeeping proteins for western blotting in adipose tissue [10]. That study used two-dimensional difference gel electrophoresis to assess protein stability between SC and OM adipose tissue across individuals. In contrast, our study focused on the stability of housekeeping proteins in isolated adipocytes, examining their performance across technical replicates, dynamic range, and relative to TP. Unlike the earlier study in whole adipose tissue, we found that PARK7, ENOA, and FAH are not optimal normalization references for isolated mature human adipocytes. Specifically, PARK7 and ENOA exhibited higher CVs across technical replicates and a narrower dynamic range compared to commonly used housekeeping proteins, such as actin and tubulin. While FAH showed low variance in technical replicates, its limited dynamic range plateaued at only 10 µg of protein loading, suggesting that its low variance may reflect insensitivity to loading differences rather than reliability. Surprisingly, GAPDH, a widely used housekeeping protein, performed poorly in our experiments, showing high variance among technical replicates, a dynamic range that deviated from expected values, and significant variability between individuals.

In our subject cohort, TP levels varied by approximately 2-fold between individuals. This variation may be attributed to the high lipid content of adipocytes, which can cause contamination during protein isolation and interfere with BCA protein quantification. In contrast, densitometry data for housekeeping proteins showed a 4- to 10-fold difference between individuals, depending on the specific protein examined. While normalizing housekeeping proteins to TP helped reduce some of these discrepancies, significant differences persisted that could not be explained by loading errors. These findings underscore considerable variability in housekeeping protein expression, even among individuals with similar metabolic profiles.

Normalization choice also impacted the interpretation of GLUT4 expression. When GLUT4 was normalized to different references, the data patterns changed substantially, emphasizing the critical importance of using a consistent normalization reference when comparing results across blots or study cohorts. For normalization to be reliable, the reference must exhibit low variability both within and between individuals. However, factors such as the molecular weight of the target protein, laboratory preferences, and experimental design can make a single housekeeping protein unsuitable for all cases. Taken together, TP offers distinct advantages as a normalization reference. It does not rely on antibodies, is not constrained by molecular weight, and provides a broadly applicable approach regardless of the protein of interest. This makes TP an attractive and versatile choice for ensuring consistent and reliable comparisons across experiments.

One limitation of stain-free technology is that it works by modifying tryptophan residues, which could affect TP quantification depending on the sample’s tryptophan content. While tryptophan metabolism varies between individuals and species, studies suggest that tryptophan levels in the proteome remain consistent within individuals of the same species [20,21]. Certain conditions, such as inflammation [22], cancer [23], kidney dysfunction [24], pregnancy [25], and treatments like interferon therapy [26] or indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors [27], are associated with altered tryptophan metabolism. However, there is currently no evidence to suggest that these changes significantly impact the tryptophan content of cellular proteins or the abundance of tryptophan-containing proteins. In cases where changes in tryptophan-containing proteins are known or suspected, alternative TP normalization methods, such as Amido Black or Ponceau Red staining (which target proteins via general electrostatic and hydrophobic interactions), or the use of stable housekeeping proteins (Table 1), may provide more reliable results.

Although tubulin outperformed TP in the presence of BSA, the fundamental issues with using housekeeping proteins as normalization references, highlighted in this study, remain. For optimal western blot normalization, it is preferable to eliminate exogenous protein contamination, such as BSA, rather than relying on housekeeping proteins as an alternative. In our experiments, excluding BSA from the adipocyte isolation protocol had no effect on adipocyte yield, however validation of removing BSA for downstream applications is needed. For experiments where the use of BSA is unavoidable, actin, as identified in this study, may serve as a more suitable normalization reference. However, whenever possible, adopting BSA-free protocols is strongly recommended to fully leverage the superior normalization capabilities of TP.

To our knowledge, this is the first study comparing TP and housekeeping protein normalization strategies in isolated primary human adipocytes. The substantial inter-individual variation in housekeeping protein expression observed in our study aligns with findings from other primary human tissue analyses: Similar variability has been reported in the human cortex [6], where actin displayed robust heterogeneity between individuals, while Ponceau TP staining provided more consistent normalization. In skeletal muscle, both GAPDH and actin demonstrated age-dependent expression decreases, while stain-free TP measurement remained stable for both inter- and intraindividual variation [8]. Similarly, placental reference proteins exhibited significant variation while total protein remained stable [9]. The biological basis for these differences likely stems from the dynamic nature of cellular metabolism. For example, metabolic enzymes such as GAPDH may vary with energy status [28,29], while structural proteins like actin could fluctuate with cell or tissue remodeling processes [30,31]. These variations are particularly relevant in adipocytes, where protein expression can be influenced by factors such as adipose depot location, BMI, age or systemic factors. The consistency of these findings across multiple primary human tissues underscores the limitations of housekeeping protein normalization and supports the broader applicability of TP normalization in human tissue analysis.

In summary, selecting an appropriate normalization strategy is essential for obtaining reliable and precise western blotting results. This study compared the normalization of GLUT4 to TP and housekeeping proteins, highlighting the significant impact of inter-individual variability in housekeeping protein expression on normalization outcomes.

While this study employed stain-free imaging to obtain TP densitometry data, alternative methods such as Coomassie Brilliant Blue, Amido Black, and Ponceau Red staining provide viable options for total protein quantification. These methods, including stain-free imaging, are generally more cost-effective than using antibodies for housekeeping proteins and preserve blot space, enabling greater multiplexing of proteins of interest.

In conclusion, we recommend total protein normalization as the gold standard for western blotting in studies involving primary mature human adipocytes, owing to its superior reliability and versatility.

Supporting information

S1 Table. Step-by-step sum normalization calculations for technical replicates and dynamic range.

(XLSX)

pone.0328136.s001.xlsx (31.9KB, xlsx)
S2 Table. Protein concentrations and loading amount for each BSA control experimental condition for Fig 1.

(DOCX)

pone.0328136.s002.docx (16.3KB, docx)
S3 Table. Clinical parameters for cohort used in Fig 4.

(DOCX)

pone.0328136.s003.docx (14.9KB, docx)
S4 Table. Clinical parameters for all samples.

(DOCX)

pone.0328136.s004.docx (16.3KB, docx)
S1 Fig. Normalization schematic for technical replicates and dynamic range.

(A) Schematic for sum normalization of technical replicates, (B) theoretical and measured data, (C) fraction of sum, (D) divided by expected. (E) Schematic for sum normalization of dynamic range, (F) theoretical and measured data, (G) fraction of sum, (H) divided by expected.

(TIF)

pone.0328136.s005.tif (1.3MB, tif)
S2 Fig. Simulation of western blot Data via seeded random number generation.

(A) Simulated raw signal intensities of a protein of interest (POI) and three different normalization references, each with a coefficient of variation (CV) of 5%, 15%, or 30%. (B) Normalized POI signal obtained by dividing the POI values by each respective normalization reference shown in (A). This demonstrates how increasing variability in the reference impacts the stability of the normalized signal, despite the POI having identical underlying variability in all cases.

(TIF)

pone.0328136.s006.tif (208.3KB, tif)
S3 Fig. BSA-contaminated samples and non-specific signal.

(A) Protein concentrations, determined with a BSA standard curve and absorption measurement using a spectrophotometer with duplicates for all conditions. (B) GLUT4 stain, shown with increased exposure to better demonstrate specific GLUT4 staining in the BSA free samples.

(TIF)

pone.0328136.s007.tif (789.3KB, tif)
S4 Fig. Technical replicates from OBHI individuals.

Coefficient of variation (CV) for total protein (TP) and respective housekeeping proteins, normalized to the sum (left panels), and for GLUT4 normalized to TP or housekeeping proteins (right panels). Each dot represents one well – a technical replicate of the same lysate sample run in separate lanes. Protein isolated from subcutaneous (SC) or omental (OM) adipocytes. Total protein demonstrated the lowest CV across all technical replicate blots, except when compared to FAH in the OM sample (A–F). When normalizing GLUT4, total protein showed the lowest CV in three blots (A, B and E), while actin (C), ENOA (D) and FAH and tubulin (F) exhibited lower CVs in three blots.

(TIF)

pone.0328136.s008.tif (1.2MB, tif)
S5 Fig

Technical replicate blots from Fig 2 and S3 Fig. (A) Subcutaneous obese normoinsulinemic (SC OBNI), total protein (TP), PARK7, GAPDH and GLUT4, (B) SC OBNI, TP, ENOA, actin and GLUT4, (C) SC OBNI, TP, FAH, tubulin and GLUT4, (D) omental (OM) OBNI, TP, PARK7, GAPDH and GLUT4, (E) OM OBNI, TP, ENOA, actin and GLUT4, (F) OM OBNI, TP, FAH, tubulin and GLUT4. Technical replicate blots from S3 Fig: (G) Subcutaneous obese hyperinsulinemic (SC OBHI), TP, PARK7, GAPDH and GLUT4, (H) SC OBHI, TP, ENOA, actin and GLUT4, (I) SC OBHI, TP, FAH, tubulin and GLUT4, (J) OM OBHI, TP, PARK7, GAPDH and GLUT4, (K) OM OBHI, TP, ENOA, actin and GLUT4, (L) OM OBHI, TP, FAH, tubulin and GLUT4.

(TIF)

S6 Fig. Dynamic range blots from Fig 3.

omental obese hyperinsulinemic (OM OBHI) lysate loaded on a gradient in 2.5 µg increments (2.5–20 µg). (A) Stain-free image of total protein (TP) and proteins stains for GLUT4, PARK7 and GAPDH, (B) GLUT4, ENOA and Actin, (C) GLUT4, FAH and tubulin.

(TIF)

pone.0328136.s010.tif (4.6MB, tif)
S7 Fig. Cohort blots from Fig 4.

(A) Stain-free image of total protein (TP) and GLUT4, PARK7 and GAPDH staining. (B) Stain-free image of TP and GLUT4, ENOA and actin staining. (C) Stain-free image of TP and GLUT4, FAH and tubulin staining.

(TIF)

pone.0328136.s011.tif (4.8MB, tif)
S1 Raw images. All original western blot images included in the manuscript, uncropped and unedited.

(PDF)

pone.0328136.s012.pdf (906.7KB, pdf)

Acknowledgments

We acknowledge the assistance of staff at Ersta Hospital CRC, research nurse Charlotte Edberg (Danderyd Hospital) and laboratory technician Lena Appelsved for her assistance in processing human biopsy samples.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Funding Statement

This work was supported by grants to K.L.S. from the Swedish Research Council (2022-01236, https://www.vr.se), the Strategic Research Program for Diabetes at Karolinska Institutet (C5471162, https://ki.se/en/srp-diabetes), the Novo Nordisk Foundation (C5475033, https://novonordiskfonden.dk/en), Vallee Foundation Scholar Award (C5471234, https://www.thevalleefoundation.org), Mark Foundation Aspire Grant (C5477023, https://themarkfoundation.org), The Swedish Cancer Society (22 2420, https://www.cancerfonden.se), the Strategic Research Program for Stem cells and Regeneration at Karolinska Institutet (C5472022, https://ki.se/en/research/research-areas-centres-and-networks/strategic-research-areas/stratregen-strategic-research-area-in-stem-cells-and-regenerative-medicine), and Knut and Alice Wallenberg Foundation (2020.0118, https://kaw.wallenberg.org/en). AT was supported by the Erling-Persson Foundation (2022 0163, https://erlingperssonsstiftelse.se). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Towbin H, Theophil S, Staehelin T, Gordon J, Gordon J, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;76(9):4350–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Burnette WN. “Western blotting”: electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem. 1981;112(2):195–203. doi: 10.1016/0003-2697(81)90281-5 [DOI] [PubMed] [Google Scholar]
  • 3.Ferguson RE, Carroll HP, Harris A, Maher ER, Selby PJ, Banks RE. Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics. 2005;5(2):566–71. doi: 10.1002/pmic.200400941 [DOI] [PubMed] [Google Scholar]
  • 4.Greer S, Honeywell R, Geletu M, Arulanandam R, Raptis L. Housekeeping genes; expression levels may change with density of cultured cells. J Immunol Methods. 2010;355(1–2):76–9. doi: 10.1016/j.jim.2010.02.006 [DOI] [PubMed] [Google Scholar]
  • 5.Gürtler A, Gürtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA. Stain-Free technology as a normalization tool in western blot analysis. Anal Biochem. 2013;433(2):105–11. [DOI] [PubMed] [Google Scholar]
  • 6.Parkin GM, Udawela M, Gibbons A, Dean B. Β-actin does not show the characteristics of a reference protein in human cortex. Electrophoresis. 2019;40(2):247–53. doi: 10.1002/elps.201800328 [DOI] [PubMed] [Google Scholar]
  • 7.Collins MA, An J, Peller D, Bowser R. Total protein is an effective loading control for cerebrospinal fluid western blots. J Neurosci Methods. 2015;251:72–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Vigelsø A, Dybboe R, Hansen CN, Dela F, Helge JW, Guadalupe Grau A. GAPDH and β-actin protein decreases with aging, making Stain-Free technology a superior loading control in Western blotting of human skeletal muscle. J Appl Physiol (1985). 2015;118(3):386–94. doi: 10.1152/japplphysiol.00840.2014 [DOI] [PubMed] [Google Scholar]
  • 9.Lanoix D, St-Pierre J, Lacasse AA, Viau M, Viau M. Stability of reference proteins in human placenta: general protein stains are the benchmark. Placenta. 2012;33(3):151–6. [DOI] [PubMed] [Google Scholar]
  • 10.Pérez-Pérez R, Pérez-Pérez R, López JA, García-Santos E, Camafeita E, Gómez-Serrano M. Uncovering suitable reference proteins for expression studies in human adipose tissue with relevance to obesity. PLOS ONE. 2012;7(1). doi: 10.1371/journal.pone.0029730 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bettencourt JW, McLaury AR, Limberg AK, Vargas-Hernandez JS, Bayram B, Owen AR. Total protein staining is superior to classical or tissue-specific protein staining for standardization of protein biomarkers in heterogeneous tissue samples. Gene Rep. 2020;19:100641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hu X, Du S, Yu J, Yang X, Yang C, Zhou D. Common housekeeping proteins are upregulated in colorectal adenocarcinoma and hepatocellular carcinoma, making the total protein a better “housekeeper”. Oncotarget. 2016;7(41):66679–88. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang JL, Li MQ, Zhang JJ, Xu C, Xu CJ. Total protein staining with Congo red as an alternative loading control for western blot analysis. Biotech Histochem. 2021:1–11. [DOI] [PubMed] [Google Scholar]
  • 14.Edwards RA, Jickling GC, Turner RJ. The light-induced reactions of tryptophan with halocompounds. Photochem Photobiol. 2002;75(4):362–8. [DOI] [PubMed] [Google Scholar]
  • 15.Hagberg CE, Li Q, Kutschke M, Bhowmick D, Kiss E, Shabalina IG. Flow cytometry of mouse and human adipocytes for the analysis of browning and cellular heterogeneity. Cell Reports. 2018;24(10):2746–2756.e5. doi: 10.1016/j.celrep.2018.07.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN. Evaluating strategies to normalise biological replicates of Western blot data. PLoS One. 2014;9(1):e87293. doi: 10.1371/journal.pone.0087293 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Eaton SL, Roche SL, Hurtado ML, Oldknow KJ, Farquharson C, Gillingwater TH. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLOS ONE. 2013;8(8). doi: 10.1371/journal.pone.0071880 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ. The use of total protein stains as loading controls: an alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods. 2008. Jul 30;172(2):250–4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Taylor SC, Posch A. The design of a quantitative western blot experiment. Biomed Res Int. 2014;2014:361590. doi: 10.1155/2014/361590 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Badawy AA-B, Guillemin GJ. Species differences in tryptophan metabolism and disposition. Int J Tryptophan Res. 2022;15:11786469221122511. doi: 10.1177/11786469221122511 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Lischka J, Schanzer A, Baumgartner M, de Gier C, Greber-Platzer S, Zeyda M. Tryptophan metabolism is associated with bmi and adipose tissue mass and linked to metabolic disease in pediatric obesity. Nutrients. 2022;14(2):286. doi: 10.3390/nu14020286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Schröcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364(1):82–90. [DOI] [PubMed] [Google Scholar]
  • 23.Platten M, Nollen EAA, Röhrig UF, Fallarino F, Opitz CA. Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019;18(5):379–401. doi: 10.1038/s41573-019-0016-5 [DOI] [PubMed] [Google Scholar]
  • 24.Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, et al. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol. 2000;279(3):F565-72. doi: 10.1152/ajprenal.2000.279.3.F565 [DOI] [PubMed] [Google Scholar]
  • 25.Badawy AA-B. Tryptophan metabolism, disposition and utilization in pregnancy. Biosci Rep. 2015;35(5):e00261. doi: 10.1042/BSR20150197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Taylor MW, Feng GS. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 1991;5(11):2516–22. doi: 10.1096/fasebj.5.11.1907934 [DOI] [PubMed] [Google Scholar]
  • 27.Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77(24):6795–811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yang J-S, Hsu J-W, Park S-Y, Li J, Oldham WM, Beznoussenko GV, et al. GAPDH inhibits intracellular pathways during starvation for cellular energy homeostasis. Nature. 2018;561(7722):263–7. doi: 10.1038/s41586-018-0475-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Sirover MA. New nuclear functions of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in mammalian cells. J Cell Biochem. 2005;95(1):45–52. doi: 10.1002/jcb.20399 [DOI] [PubMed] [Google Scholar]
  • 30.Hyrskyluoto A, Vartiainen MK. Regulation of nuclear actin dynamics in development and disease. Curr Opin Cell Biol. 2020;64:18–24. [DOI] [PubMed] [Google Scholar]
  • 31.Hallows KR, Law FY, Packman CH, Knauf PA. Changes in cytoskeletal actin content, F-actin distribution, and surface morphology during HL-60 cell volume regulation. J Cell Physiol. 1996;167(1):60–71. doi: [DOI] [PubMed] [Google Scholar]

Decision Letter 0

V V Sathibabu Uddandrao

PONE-D-24-50811

Superior normalization using total protein for western blot analysis of human adipocytes

PLOS ONE

Dear Dr. Kirsty Spalding,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we have decided that your manuscript does not meet our criteria for publication and must therefore be rejected.

Specifically:

I regret to inform you that your manuscript does not have the scientific significance required by this journal and we must therefore reject it.

I am sorry that we cannot be more positive on this occasion, but hope that you appreciate the reasons for this decision.

For your information and guidance, any specific comments explaining why I have reached this decision and those received from reviewers, if available, are listed at the end of this letter.

Kind regards,

Dr. V. V. Sathibabu Uddandrao

Academic Editor

PLOS ONE

[Note: HTML markup is below. Please do not edit.]

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: I Don't Know

Reviewer #2: Yes

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

Reviewer #1: The introduction effectively sets up the study's objective, emphasizing the need for improved normalization strategies in Western blot analysis. Consider briefly addressing why TP normalization has not yet become a universal standard, despite its advantages, to contextualize the significance of this research.

The methods section is comprehensive, but some procedural descriptions, such as the justification for excluding BSA in adipocyte isolation, could benefit from further elaboration. For example, explain how the adjusted protocol impacts the broader applicability of the findings.

In the protein extraction and quantification section, it might help to clarify why the BCA assay was chosen over other protein quantification methods.

The results are thorough, with clear visualizations supporting the text. However, Figure legends could provide more contextual explanations of key observations for readers unfamiliar with the technical nuances of Western blot normalization.

Some variability in TP and housekeeping proteins across patient samples is discussed, but it would be helpful to hypothesize more concretely on the biological factors contributing to these differences.

Consider summarizing the key advantages of TP normalization over individual housekeeping proteins in a concise table or schematic for clarity.

The discussion appropriately highlights the benefits of TP normalization. It would strengthen the manuscript to compare these findings more explicitly with studies employing other normalization methods in similar contexts (e.g., specific adipocyte studies).

Addressing the potential limitations of TP normalization due to tissue-specific tryptophan content is valuable. Consider discussing whether this limitation could extend to clinical applications or other experimental designs.

The supplementary figures are well-constructed, but it may be helpful to integrate key supplementary findings directly into the main figures for a more cohesive narrative.

Ensure all figure captions are self-contained, explaining abbreviations and experimental conditions in detail.

The conclusion strongly advocates for TP normalization but could also acknowledge scenarios where housekeeping proteins might still be appropriate, particularly for specific experimental designs.

Ensure consistency in terminology and abbreviations throughout the manuscript.

Revisit the statistical analysis details to ensure they are sufficiently described, particularly regarding how variability was quantified across replicates and normalization references.

The ethics statement is clear, but more details on the demographic and clinical background of the patient cohort might enhance reproducibility and relevance.

Reviewer #2: The authors in their studies clearly revealed that TP (Total Protein) normalization methods in western blotting are far superior to housekeeping (GLUT4), actin, and tubulin protein-based normalization methods, including BSA contaminations.

The methods that they suggested are more reliable and cost-effective, as they are not using any antibodies in their work and are strain-free too.

But studies were limited to only primary mature human adipocytes. No more comparisons/discussions with with other cell types of human samples.

Noise eliminations and contaminations, like with BSA proteins, were discussed exhaustively, but no data was not shown for noise elimination or contamination removal.

Reviewer #3: Westerberg et al. have produced a manuscript investigating two approaches to Western blot normalization, housekeeping protein normalization and total protein normalization, in adipocytes.

The concept of the manuscript is not particularly novel, as stain-free total protein normalization has been a common way of normalizing Western blot data for more than ten years. However, it could still be of particular interest if done rigorously and in a way where a generalizable improvement can be shown in adipocytes. In this study, there are, unfortunately, too many issues with the experimental design.

i) The study relies on commercially available antibodies, and it is of utmost significance to ensure that the antibodies used in the experiments are thoroughly validated for the type of study performed. There is no discussion regarding the validation of the antibodies used, and there is only accessible validation data for the antibody targeting FAH (#PA5-42049). Additionally, this antibody is referred to as an anti-FAA antibody even though the target referenced by the vendors is FAH. There is no common gene abbreviation called FAA. This antibody is also disregarded due to signal saturation, which could easily be avoided by protocol optimization. A few recommended readings on antibody validation are:

- “Antibody validation” by Bordeaux et al. from 2010, BioTechniques.

- “Enhanced validation of antibodies for research applications” by Edfors et al. from 2018, Nature Communications.

- “Antibodypedia, a Portal for Sharing Antibody and Antigen Validation Data” by Björling and Uhlén from 2008, Molecular & Cellular Proteomics.

ii) The authors only investigate the normalization in the context of one protein target. The lack of different protein targets subjected to normalization nullifies any generalization of the findings, and making any generalized claims without investigating at least a smaller data set of ten different target proteins would be ill-advised.

iii) The manuscript does not have a proper statistical evaluation that supports the claim of improved accuracy with total protein normalization, and there are no established reference values for the samples that can indicate if the observed intensities actually reflect the truth.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

- - - - -

For journal use only: PONEDEC3

PLoS One. 2025 Jul 22;20(7):e0328136. doi: 10.1371/journal.pone.0328136.r002

Author response to Decision Letter 1


30 Jan 2025

The response to reviewers includes figures and information that loses format if pasted into this space. Instead the response to reviewers has been uploaded as PDF file 'Response to reviewers.pdf'.

Attachment

Submitted filename: Response to reviewers.pdf

pone.0328136.s014.pdf (404KB, pdf)

Decision Letter 1

Jérôme Robert

Dear Dr. Spalding,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 20 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Jérôme Robert, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data.

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels.

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

5. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access."

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #1: All comments have been addressed

Reviewer #3: (No Response)

Reviewer #4: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #1: Yes

Reviewer #3: No

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #3: No

Reviewer #4: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

Reviewer #1: I have gone through with the revised manuscript and found it suitable for the publication. Authors have addressed all comments

Reviewer #3: The authors seem to have misunderstood the comment regarding assessing normalization in multiple target proteins. In the study, normalization is only evaluated in the context of GLUT4. To claim that the normalization is superior for experiments conducted in primary human adipocytes, the normalization strategies must be assessed for multiple proteins of variable expression between individuals. Without this comparison, the claims of superior normalization can only be applied to GLUT4 specifically.

Additionally, there is a significant need to discuss the validation of the antibodies used beyond “all commercially validated” when using these as the basis for comparing different normalization strategies. As stated in the previous reviewer comments, there is only publicly available validation data for one of the antibodies, and a discussion and justification for the choice of these antibodies should be included in the manuscript.

As the authors state in their response, they have done a robust statistical assessment of the measurement stability. Still, stability is not the same thing as accuracy. Without any established reference values for GLUT4 in the different samples from individuals (preferably with a different methodology), there is no evidence of improved accuracy in the measurements. Accuracy is a measurement of how well the quantification reflects the actual amount of the analyte. Accuracy can, for example, be assessed by measuring the samples with an orthogonal method or by spiking a sample with different amounts of a recombinant protein. This is of significant importance when working with normalization strategies, as the normalization directly impacts the measurement values obtained from an analysis.

Reviewer #4: The manuscript entitled “Superior normalization using total protein for western blot analysis of human

adipocytes” demonstrates that total protein might be a better normalization element in WB quantification of protein lysates when studying adipose tissue and adipocytes. In general, the experiments are well designed and presented. I have few questions and comments that may improve the readability of the manuscript:

• Lines 246-253 “Overexposure of the blot showed that the expected GLUT4 signal (~54 kDa) was clearly present in the BSA-free samples while the BSA-isolated samples showed non-specific bands at ~60 kDa (S2B Fig). These results can be explained by anti-GLUT4 antibody binding non-specifically to BSA (65 kDa) leading to false positives in BSA-isolated samples but not in BSA-free samples. Thus, subsequent experiments within this study used BSA-free samples, accentuating the importance of limiting BSA, or other protein contaminants, in western blotting”. Is there a reason why the authors speculate that is the anti-GLUT4 that is cross-reacting with BSA and not the secondary antibody?

• I am curious if is there a technical/biological reason for GLUT4 selection as target gene? Notoriously, WB of membrane proteins are less clean and often characterized by double bands not very sharped associated to the glycosylated and non-glycosylated forms.

• Figure 2 shows technical replicates from OBNI individuals. Do I understand correctly that each dot represent different runs from the same lysate sample? If so, please add/reiterate this when you describe the results and in the figure legend.

• I do not see a callout for table 1.

• Sometimes μg was reported as ug (e.g., line 263, line 309). Please correct.

• Sometimes numbers were reported with comma (e.g., 2,5 – line 300), sometimes with dot (e.g., 27.3, line 320). I suggest using everywhere the dot format.

**********

what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: Yes:  Umesh Kumar

Reviewer #3: No

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 Jul 22;20(7):e0328136. doi: 10.1371/journal.pone.0328136.r004

Author response to Decision Letter 2


25 Jun 2025

Rebuttal PONE-D-24-50811R1

“Superior normalization using total protein for western blot analysis of human adipocytes”

June 18, 2025

Stockholm, Sweden

Dear Editor and Reviewers,

Thank you for taking the time to review our work and for your thoughtful feedback.

Please find below our point-by-point response to comments (author response in blue) as well as our response to the general comments requested of the reviewers.

All line references refer to the clean version of the manuscript.

Thank you again for this constructive review process, we believe the manuscript has been substantially strengthened as a result.

Kind regards,

Kirsty

Kirsty Spalding

Professor | Vice-Chair Department of Cell and Molecular Biology

Wallenberg Scholar

Karolinska Institutet

Biomedicum B7 | Solnavägen 9 | SE-171 65 Solna

Aula Medica | Nobels väg 6 | Floor 7 | SE-171 77 Stockholm

Phone: +46 (0)70 437 1542

E-mail: kirsty.spalding@ki.se

Karolinska Institutet – a medical university

Reviewer 1

I have gone through with the revised manuscript and found it suitable for the publication. Authors have addressed all comments.

We thank you for your positive evaluation and constructive comments, which we believe have helped improve the quality and clarity of our work.

Reviewer 3

1. The authors seem to have misunderstood the comment regarding assessing normalization in multiple target proteins. In the study, normalization is only evaluated in the context of GLUT4. To claim that the normalization is superior for experiments conducted in primary human adipocytes, the normalization strategies must be assessed for multiple proteins of variable expression between individuals. Without this comparison, the claims of superior normalization can only be applied to GLUT4 specifically.

Response to Reviewer 3, Comment 1

Thank you for this important point. We agree that demonstrating the generalisability of our normalization strategy beyond a single protein target strengthens our conclusions. To address this, we have:

(i) Clarified the role of GLUT4 as an illustrative example, not the sole basis for our claims.

(ii) Added a simulation-based analysis to show how reference-protein variability affects normalized measurements irrespective of the target protein.

We would like to clarify that GLUT4 was included merely as a “real-world” example of our workflow, not to imply that our conclusions apply only to GLUT4. In practice, the benefits of total-protein normalization, namely, its superior technical reproducibility, increased inter-individual stability, and broader dynamic range, are independent of the particular protein being measured.

To illustrate this universality, we generated simulated Western-blot datasets with controlled variability. Using the Box-Muller transformation, we created a “protein of interest” (POI) dataset with a realistic technical CV of 19.9% (mean = 1) and three randomized independent “reference” datasets with CVs of 5%, 15%, and 30%. We then normalized the POI values to each reference and recalculated CVs.

(i) Stable reference (5% CV): Normalization maintained high precision (final CV = 16.6%), closely matching the POI’s original variability.

(ii) Moderately variable reference (15% CV): Normalization inflated variability (final CV = 30.6%).

(iii) Highly variable reference (30% CV): Normalization further increased variability (final CV = 47%), a 2.8-fold loss of precision compared to the stable reference (16.6% stable vs 47% highly variable).

These results (now shown in the revised manuscript’s Methods, starting line 199; Results, starting line 210; and New S2 Fig.) demonstrate that reference-protein stability directly governs the precision of normalized measurements, regardless of which target protein is analyzed. Importantly, all simulations assume identical loading and isolate only the effects of reference variability on quantification precision. While biological factors (e.g., correlations between target and reference expression) are not accounted for in the model here, our findings establish a general analytical principle: total-protein normalization minimizes technical noise and maximizes reproducibility across any protein target.

New S2 Fig. Simulation of Western-blot normalization via seeded random data. (A) Raw signal intensities for a protein of interest (POI) and three normalization references with increasing coefficients of variation (CV = 5 %, 15 %, 30 %). (B) Normalized POI signals (POI/reference) for each CV level. As reference variability rises, normalized-signal stability deteriorates, even though the POI’s underlying variability remains constant.

2. Additionally, there is a significant need to discuss the validation of the antibodies used beyond “all commercially validated” when using these as the basis for comparing different normalization strategies. As stated in the previous reviewer comments, there is only publicly available validation data for one of the antibodies, and a discussion and justification for the choice of these antibodies should be included in the manuscript.

Response to Reviewer 3, Comment 2

We appreciate the reviewer’s emphasis on rigorous antibody validation. Below, we summarise both published evidence and our in-house checks for each antibody used (we are happy to include images from all referenced figures in our rebuttal if the editor/reviewer wishes):

GLUT4 antibody (66846-1-Ig, Proteintech)

• Literature support: Cited in >90 peer-reviewed studies for Western blot (WB) and immunocytochemistry (ICC) with consistent detection of the 45–55 kDa GLUT4 band (see list: https://www.citeab.com/antibodies/6638026-66846-1-ig-glut4-monoclonal-antibody?des=3de7421913174b6d).

• Manufacturer data: Raised against AA 1–100 of human GLUT4; minimal cross-reactivity to other GLUT isoforms (datasheet).

PARK7 antibody (ab18257, Abcam)

• Vendor validation: Abcam’s KO-cell analysis shows complete signal loss in PARK7 KO HAP1 cells (https://www.abcam.com/en-us/products/primary-antibodies/park7-dj1-antibody-ab18257).

• Cross-species: Validated on human, mouse, and rat lysates.

FAH antibody (PA5-42049, Thermo Fisher)

• Knockdown validation: Demonstrated in DOI:10.1002/mgg3.2090, Fig. 3A.

Housekeeping-protein antibodies

• GAPDH (12004167), Actin (12004163), Tubulin (12004165):

Literature usage: Each antibody has been used extensively (GAPDH: 25 studies; Actin: 50; Tubulin: 44, see https://www.citeab.com/…), consistently yielding single bands at expected weights.

Practical constraints: True KO/knockdown is often not feasible for essential proteins; instead, we rely on extensive community usage and concordant fractionation data (e.g., purity markers in cytosolic vs. nuclear fractions).

ENO1 antibody (MBS9231722, MyBioSource)

• Overexpression validation: Shown in Blood 2008 (10.1182/blood-2008-08-170837, Fig. 5A).

While we have selected antibodies with strong literature precedent, we recognise that no single antibody validation is perfect. This limitation further motivates our adoption of total-protein normalization: it minimises dependence on any one antibody’s specificity and provides a more robust, reproducible baseline across experiments.

3. As the authors state in their response, they have done a robust statistical assessment of the measurement stability. Still, stability is not the same thing as accuracy. Without any established reference values for GLUT4 in the different samples from individuals (preferably with a different methodology), there is no evidence of improved accuracy in the measurements. Accuracy is a measurement of how well the quantification reflects the actual amount of the analyte. Accuracy can, for example, be assessed by measuring the samples with an orthogonal method or by spiking a sample with different amounts of a recombinant protein. This is of significant importance when working with normalization strategies, as the normalization directly impacts the measurement values obtained from an analysis.

Response to Reviewer 3, Comment 3

Thank you for this insightful point. We apologise for any lack of clarity regarding the scope of our analysis. Our goal was not to determine the absolute abundance of GLUT4 in adipocyte lysates, but rather to use GLUT4 as a representative “real-world” example to illustrate how the choice of normalization reference, particularly different housekeeping proteins, can dramatically influence the precision of normalized protein measurements across individuals.

To make this explicit, we have:

1. Emphasised the illustrative nature of GLUT4

We have revised the text to state clearly that GLUT4 serves only as an example target. Our aim is to highlight variability in normalization references, not to benchmark GLUT4 quantification accuracy per se.

2. Linked back to our simulation analysis

As detailed in our response to Comment 1, we now include simulated Western-blot datasets showing that, even with identical underlying protein signals, increasing variability in the reference inflates normalized-signal imprecision. This controlled demonstration (New S2 Fig) underscores that reference stability, not the target protein, drives normalized-measurement precision.

3. Clarified Figure 4’s purpose

We have updated the legend (line 386) and main text to specify that Figure 4D-F illustrates inter-individual variability of six housekeeping proteins, before and after total-protein normalization. These panels are intended to show that:

- Normalizing housekeeping proteins to total protein only partly reduces their inter-patient variability.

- Different housekeeping proteins display distinct variability profiles across donors.

- Such variability violates the assumption that a normalization reference is stable and independent of biological conditions.

We agree that evaluating accuracy (i.e., closeness to the true protein amount) would require orthogonal methods or spike-in standards. While this is beyond the present study’s scope, our simulation and real-data analyses together establish a compelling case that total-protein normalization minimizes technical noise and yields more reproducible quantification, an essential prerequisite for accuracy in any downstream measurement. We have made these clarifications in the Methods section (line 193), the Results section (line 423), and the Discussion section (line 530) of the revised manuscript to ensure that the distinction between precision (measurement variability) and accuracy (true-value agreement) is fully transparent.

Reviewer 4:

1. Lines 246-253 “Overexposure of the blot showed that the expected GLUT4 signal (~54 kDa) was clearly present in the BSA-free samples while the BSA-isolated samples showed non-specific bands at ~60 kDa (S2B Fig). These results can be explained by anti-GLUT4 antibody binding non-specifically to BSA (65 kDa) leading to false positives in BSA-isolated samples but not in BSA-free samples. Thus, subsequent experiments within this study used BSA-free samples, accentuating the importance of limiting BSA, or other protein contaminants, in western blotting”. Is there a reason why the authors speculate that is the anti-GLUT4 that is cross-reacting with BSA and not the secondary antibody?

Response to Reviewer 4, Comment 1

Thank you for pointing this out. You are correct that we cannot definitively attribute the cross-reactivity to the primary versus the secondary antibody without additional experiments. To avoid overinterpretation, we have revised the text (Lines 279–285) as follows:

“Overexposure of the blot showed that the expected GLUT4 signal (~54 kDa) was clearly present in BSA-free samples, while BSA-isolated samples exhibited a non-specific band at ~60 kDa (S2B Fig). These results can be explained by non-specific antibody binding to BSA (65 kDa), leading to false positives in BSA-isolated samples but not in BSA-free samples. Thus, subsequent experiments within this study used BSA-free samples, accentuating the importance of limiting BSA, or other protein contaminants, in western blotting.”

This wording removes any implication about which antibody is responsible, accurately reflecting our observations. Thank you for helping us clarify this point.

2. I am curious if is there a technical/biological reason for GLUT4 selection as target gene? Notoriously, WB of membrane proteins are less clean and often characterised by double bands not very sharped associated to the glycosylated and non-glycosylated forms.

Response to Reviewer 4, Comment 2

Thank you for this thoughtful question. GLUT4 was chosen purely as a methodological test case because, in our hands, it yields robust, clear, and highly reproducible bands under our optimised western-blot protocol for mature human adipocytes. We acknowledge that membrane proteins often display glycosylation-related doublets or diffuse bands; however, GLUT4 consistently produces interpretable signals across multiple donor samples, making it well suited for evaluating normalization strategies.

Importantly, the intent was not to draw any biological conclusions about GLUT4 regulation, but rather to use a realistic adipocyte protein target to benchmark how different normalization approaches perform.

3. Figure 2 shows technical replicates from OBNI individuals. Do I understand correctly that each dot represent different runs from the same lysate sample? If so, please add/reiterate this when you describe the results and in the figure legend.

Response to Reviewer 4, Comment 3

Thank you for the suggestion. We have clarified both the figure legend and the Results text to make this explicit:

Figure 2 legend (line 316) now reads:

“Each dot represents one well - a technical replicate of the same lysate sample run in separate lanes.”

Results section (line 292) now changed to read: “First, the assessment involved technical replicates, where each well in a gel was loaded with 10 µg of protein from the same sample. Samples were obtained from four different individuals: two obese hyperinsulinemic (OBHI) patients (one subcutaneous (SC) and one omental (OM)) and two obese normoinsulinemic (OBNI) patients (one SC and one OM). Each sample was analyzed across three separate blots to assay all housekeeping proteins, allowing for the normalization of GLUT4 levels to two housekeeping proteins and TP within each blot.”

We have made the analogous update to S4 Fig legend (line 655) for consistency.

4. I do not see a callout for table 1.

Response to Reviewer 4, Comment 4

Table 1 is cited twice in the current version of the manuscript: first on line 427 and again on line 498. It is initially referenced in the final paragraph of the Results section—not to present new data, but to provide a summary of the advantages and disadvantages of different normalization references across various experimental designs. We acknowledge that, because the table is introduced relatively late and does not contain original data, the callout may be easily overlooked. However, we believe that its current placement is appropriate and serves its intended purpose within the manuscript structure.

5. Sometimes μg was reported as ug (e.g., line 263, line 309). Please correct.

Response to Reviewer 4, Comment 5

We appreciate your attention to detail and have corrected all instances of “ug” to “µg” throughout the manuscript.

6. Sometimes numbers were reported with comma (e.g., 2,5 – line 300), sometimes with dot (e.g., 27.3, line 320). I suggest using everywhere the dot format.

Response to Reviewer 4, Comment 6

We appreciate the reviewer’s attention to consistency and have replaced all instances of numbers reported with a comma to the dot format throughout the manuscript.

General questions from the journal:

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Acce

Attachment

Submitted filename: Response to reviewers Westerberg et al..pdf

pone.0328136.s015.pdf (224.5KB, pdf)

Decision Letter 2

Jérôme Robert

Superior normalization using total protein for western blot analysis of human adipocytes

PONE-D-24-50811R2

Dear Dr. Spalding,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jérôme Robert, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Jérôme Robert

PONE-D-24-50811R2

PLOS ONE

Dear Dr. Spalding,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jérôme Robert

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Step-by-step sum normalization calculations for technical replicates and dynamic range.

    (XLSX)

    pone.0328136.s001.xlsx (31.9KB, xlsx)
    S2 Table. Protein concentrations and loading amount for each BSA control experimental condition for Fig 1.

    (DOCX)

    pone.0328136.s002.docx (16.3KB, docx)
    S3 Table. Clinical parameters for cohort used in Fig 4.

    (DOCX)

    pone.0328136.s003.docx (14.9KB, docx)
    S4 Table. Clinical parameters for all samples.

    (DOCX)

    pone.0328136.s004.docx (16.3KB, docx)
    S1 Fig. Normalization schematic for technical replicates and dynamic range.

    (A) Schematic for sum normalization of technical replicates, (B) theoretical and measured data, (C) fraction of sum, (D) divided by expected. (E) Schematic for sum normalization of dynamic range, (F) theoretical and measured data, (G) fraction of sum, (H) divided by expected.

    (TIF)

    pone.0328136.s005.tif (1.3MB, tif)
    S2 Fig. Simulation of western blot Data via seeded random number generation.

    (A) Simulated raw signal intensities of a protein of interest (POI) and three different normalization references, each with a coefficient of variation (CV) of 5%, 15%, or 30%. (B) Normalized POI signal obtained by dividing the POI values by each respective normalization reference shown in (A). This demonstrates how increasing variability in the reference impacts the stability of the normalized signal, despite the POI having identical underlying variability in all cases.

    (TIF)

    pone.0328136.s006.tif (208.3KB, tif)
    S3 Fig. BSA-contaminated samples and non-specific signal.

    (A) Protein concentrations, determined with a BSA standard curve and absorption measurement using a spectrophotometer with duplicates for all conditions. (B) GLUT4 stain, shown with increased exposure to better demonstrate specific GLUT4 staining in the BSA free samples.

    (TIF)

    pone.0328136.s007.tif (789.3KB, tif)
    S4 Fig. Technical replicates from OBHI individuals.

    Coefficient of variation (CV) for total protein (TP) and respective housekeeping proteins, normalized to the sum (left panels), and for GLUT4 normalized to TP or housekeeping proteins (right panels). Each dot represents one well – a technical replicate of the same lysate sample run in separate lanes. Protein isolated from subcutaneous (SC) or omental (OM) adipocytes. Total protein demonstrated the lowest CV across all technical replicate blots, except when compared to FAH in the OM sample (A–F). When normalizing GLUT4, total protein showed the lowest CV in three blots (A, B and E), while actin (C), ENOA (D) and FAH and tubulin (F) exhibited lower CVs in three blots.

    (TIF)

    pone.0328136.s008.tif (1.2MB, tif)
    S5 Fig

    Technical replicate blots from Fig 2 and S3 Fig. (A) Subcutaneous obese normoinsulinemic (SC OBNI), total protein (TP), PARK7, GAPDH and GLUT4, (B) SC OBNI, TP, ENOA, actin and GLUT4, (C) SC OBNI, TP, FAH, tubulin and GLUT4, (D) omental (OM) OBNI, TP, PARK7, GAPDH and GLUT4, (E) OM OBNI, TP, ENOA, actin and GLUT4, (F) OM OBNI, TP, FAH, tubulin and GLUT4. Technical replicate blots from S3 Fig: (G) Subcutaneous obese hyperinsulinemic (SC OBHI), TP, PARK7, GAPDH and GLUT4, (H) SC OBHI, TP, ENOA, actin and GLUT4, (I) SC OBHI, TP, FAH, tubulin and GLUT4, (J) OM OBHI, TP, PARK7, GAPDH and GLUT4, (K) OM OBHI, TP, ENOA, actin and GLUT4, (L) OM OBHI, TP, FAH, tubulin and GLUT4.

    (TIF)

    S6 Fig. Dynamic range blots from Fig 3.

    omental obese hyperinsulinemic (OM OBHI) lysate loaded on a gradient in 2.5 µg increments (2.5–20 µg). (A) Stain-free image of total protein (TP) and proteins stains for GLUT4, PARK7 and GAPDH, (B) GLUT4, ENOA and Actin, (C) GLUT4, FAH and tubulin.

    (TIF)

    pone.0328136.s010.tif (4.6MB, tif)
    S7 Fig. Cohort blots from Fig 4.

    (A) Stain-free image of total protein (TP) and GLUT4, PARK7 and GAPDH staining. (B) Stain-free image of TP and GLUT4, ENOA and actin staining. (C) Stain-free image of TP and GLUT4, FAH and tubulin staining.

    (TIF)

    pone.0328136.s011.tif (4.8MB, tif)
    S1 Raw images. All original western blot images included in the manuscript, uncropped and unedited.

    (PDF)

    pone.0328136.s012.pdf (906.7KB, pdf)
    Attachment

    Submitted filename: Response to reviewers.pdf

    pone.0328136.s014.pdf (404KB, pdf)
    Attachment

    Submitted filename: Response to reviewers Westerberg et al..pdf

    pone.0328136.s015.pdf (224.5KB, pdf)

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES